Skip to content
Menu

Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $117

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $102 to $117.

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $102 to $117.

Read at benzinga.com